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The opinion article from Prof. Pritchard casts a much needed
critical-eye over the current status and future of clinical ‘‘worm
therapy’’ (Pritchard, 2012). The use of experimental helminth in-
fections or helminth-derived products as therapeutics is a promis-
ing and expanding ﬁeld of research, with signiﬁcant potential for
the treatment of inﬂammatory, allergic and autoimmune disorders.
Chronic helminth infections, particularly those of the gastrointest-
inal tract, are increasingly accepted as part of the natural ﬂora with
which humans have co-evolved over millennia. Thus, helminth in-
fections are inherently associated with the so-called ‘‘hygiene hy-
pothesis’’ that underlies much of the current etiological thinking
regarding the increased prevalence of allergy and autoimmunity
in the western world. This theory has been strengthened by a range
of epidemiological studies demonstrating a link between the loss
of helminth infections and the rise of allergic and inﬂammatory
diseases in developing countries, as well as by a multitude of la-
boratory studies in murine models and to a lesser extent in hu-
mans. These studies demonstrate the efﬁcacy of live helminth
infections, administration of secreted helminth products or of de-
ﬁned, recombinantly produced helminth molecules in the suppres-
sion of a wide range of inﬂammatory diseases.
Given the abundance of data already accrued it now seems
appropriate that the scientiﬁc community reﬂects upon the ad-
vances made in recent years and considers how best to proceed
in order to reach the ultimate goal of bringing ‘‘worm therapy’’ into
the clinics, and to the patients who could potentially beneﬁt
from it.Published by Elsevier Ltd.
: +49 3020936051.
(M.R. Hepworth).
Open ac2. Where do we go from here?
For ‘‘worm therapy’’ to be successfully transitioned into the
clinics it is necessary to consider short-term beneﬁts as well as
long-term priorities. In the short term it may indeed be beneﬁcial,
as suggested by Prof. Pritchard, to focus on the administration of live
helminths. There are a signiﬁcant number of patients suffering from
autoimmune, inﬂammatory and allergic diseases for whom conven-
tional therapies have been unsuccessful. As such many patients are
willing to try experimental treatments, including ‘‘worm therapy’’.
There are even documented cases of patientswho have sought to in-
fect themselves with gastrointestinal nematodes in order to treat
symptoms of severe inﬂammatory disease (Broadhurst et al.,
2010). In the short-term validated safe worm therapies such as
Trichuris suis ova (TSO) shouldbe investigated on amuch larger scale
in the clinics to determine efﬁcacy, therapeutic longevity and safety.
Indeed the results from initial trials with TSO in patients with
inﬂammatoryboweldisease (Summers et al., 2005a,b), coupledwith
recent smaller scale trials inmultiple sclerosis patients (Benzel et al.,
2011; Fleming et al., 2011) suggest TSOmay be viable as a treatment
for inﬂammatory disease. However, it should be noted that a study
by Bager et al. in allergic rhinitis patients failed to show any signiﬁ-
cant improvement in disease symptoms following TSO therapy
(Bager et al., 2010). The outcomesof a number of ongoing clinical tri-
als currently investigating TSO treatment are eagerly anticipated.
Nonetheless, it is our opinion that although developing live
worm therapy may be immediately attractive, the characterisation
of deﬁned and targeted therapies based on helminth-derived
molecules should prove more beneﬁcial and preferable in the long
term. Application of live parasites has several caveats, not least
inevitable problems with patient compliance. Parasitic helminthscess under CC BY-NC-ND license.
Fig. 1. Strategy for the development of helminth-derived therapies for clinical application.
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helminths is likely to result in signiﬁcant side effects associated
with tissue damage and inﬂammation. Indeed, Bager et al. have re-
ported signiﬁcant side effects in patients receiving TSO therapy –
including diarrhoea and abdominal pain (Bager et al., 2011).
Although unlikely, it is also still unclear whether T. suis may estab-
lish and persist in the human host (Kradin et al., 2006).
In a limited number of cases the speciﬁc immunomodulatory
protein that mediates immunosuppression during helminth infec-
tions has been identiﬁed – such as the ﬁlarial immunomodulators
Av17 and ES-62 (Harnett and Harnett, 2009; Klotz et al., 2011). In
addition, the recent publication of the transcriptomes and secreto-
mes of several commonly studied helminths will no doubt lead to
the identiﬁcation of a number of new immunomodulatory prod-
ucts (Hewitson et al., 2008, 2011b; Cantacessi et al., 2011a,b). Thus,
single deﬁned helminth products can be characterised in order to
elucidate their mechanisms of immunosuppression and the best
candidates developed for therapeutic use (Fig. 1).
Helminth infections induce a wide range of immune regulatory
mechanisms and have been shown to inhibit a variety of inﬂamma-
tory and allergic diseases via the induction of CD4+ regulatory T
cells (Grainger et al., 2010), CD8+ regulatory cells (Metwali et al.,
2006), regulatory B cells (Wilson et al., 2010) and the modulation
of a wide range of innate cell types including macrophages
(Schnoeller et al., 2008; Klotz et al., 2011), dendritic cells (Segura
et al., 2007; Hang et al., 2010) and mast cells (Melendez et al.,
2007), amongst others. The modulatory activity of any helminth-
derived therapy will have to be balanced against unwanted sup-
pressive effects on protective immune responses, vaccination and
anti-tumour immunity. Indeed, regulatory T cells induced by hel-
minth infection have been shown to suppress the response to
BCG vaccination and to concurrent malaria infection in children
in endemic regions (Wammes et al., 2010). Helminth infections
have also been shown to interfere with concurrent immunity to
pathogenic bacterial species by modulation of the immune system
(Weng et al., 2007). In addition, more focus should be placed on de-
veloping a better understanding of the interactions of gastrointest-
inal helminth infections with the intestinal microbiota with which
they share the intestinal niche. Maintaining the balance of intest-
inal ﬂora is central to the prevention of intestinal inﬂammatorydisorders and for the regulation and maintenance of immune
homeostasis. Indeed helminth infection has been shown to result
in changes in the composition of intestinal bacteria including in-
creased frequency of Lactobacillaceae (Walk et al., 2010) and Enter-
obacteriaceae species (Rausch and Hartmann, unpublished data).
Indeed, T. suis infection induces signiﬁcant changes in the host mi-
crobiota, which are likely to be of clinical importance (Wu et al.,
2012; Li et al., 2012). Thus, priority needs to be given to developing
therapies that modulate only the unwanted inﬂammatory response
(i.e. allergic or autoimmune response) while maintaining otherwise
normal immunity in the same patient.3. Can deﬁned helminth immunomodulators be effective as
therapeutics?
Central to Prof. Pritchard’s critique is the assumption that the use
of deﬁned helminth derived immunomodulatory products as thera-
peutics is doomed to failure as such products will be neutralised and
rendered ineffective by the host immune response. In contrast, Prof.
Pritchard argues that live worm therapies should be given priority in
the short term as they have shown some promise in the clinics and
hopefully, can be made available to patients in the near future. How-
ever, one problem with this approach is that live parasite infections
result in tissue damage and the induction of danger signals and pro-
inﬂammatory stimuli thus, leading to inﬂammation. Furthermore,
the host is exposed to the full spectrum of helminth-derived prod-
ucts including potent antigens, inﬂammatory stimuli and potentially
disease causing allergens in addition to the desired helminth immu-
nomodulators. It is widely acknowledged that the ability of hel-
minths to modulate the immune system and suppress bystander
inﬂammatory diseases is due to their production of immunomodula-
tory products that induce a variety of suppressive cell types in the
host that maintain immune suppression and prevent parasite eradi-
cation. Thus, if Prof. Pritchard’s argument that current candidate hel-
minth products would be neutralised by antibodies in the host is
correct then it would also be expected that live ‘‘worm therapy’’ in
patients would also be ineffective as the very same helminth derived
immunomodulators that mediate immunosuppression would also
be neutralised during infection and become ineffective.
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infections or ﬁlarial infections in both humans and rodents has
been demonstrated to be due to the effects of immunomodulatory
products that occur in the presence of a full host adaptive immune
response and the production of antibodies. Indeed IgG and IgE sub-
class antibodies were produced against T. suis derived products by
patients during clinical trials with TSO (Bager et al., 2010, 2011),
but nonetheless the effect of TSO therapy has been shown to per-
sist and maintain remission in treated patients long after the pro-
duction of host antibodies (Summers et al., 2005a,b). Thus, this
suggests that either the activity of helminth immunomodulators
can persist even in the presence of antibodies that recognise them,
or that non-immunogenic products may be present that mediate
immunosuppression. In line with this Grainger et al. found that
helminth derived TGF-b activity was still required to maintain
immunosuppression even during the late chronic stages of gastro-
intestinal helminth infection. Blockade of TGF-b signalling, but not
neutralisation of host derived TGF-b cytokine, during chronic infec-
tion resulted in a restoration of Th2 cytokine production and a re-
duced parasite burden (Grainger et al., 2010). Similarly, abrogation
of long-term ﬁlarial infection by drug treatment results in in-
creased allergic responses and immunoreactivity in de-wormed
patients suggesting a persistent and active immunosuppression
of anti-helminth responses during chronic ﬁlarial infections (van
den Biggelaar et al., 2004; Flohr et al., 2009). Thus, helminth de-
rived immunomodulatory activity appears to be evident long after
the development of host adaptive immune responses suggesting
the activity of key worm derived immunomodulators may not be
neutralised by the host immune system. Indeed, Prof. Pritchard
acknowledges that the effects of live worm therapy seem to be
long lasting and therefore, that non-immunogenic or non-neutra-
lised helminth derived products may exist and priority should be
placed on identifying these products.
Many helminth derived products are relatively poor antigens in
terms of their ability to activate antigen presenting cells and in fact
can down modulate the expression of co-stimulatory markers in-
duced by other stimuli such as TLR-ligands (Reviewed by (Carvalho
et al., 2009). Thus, the activation and presentation of helminth-de-
rived antigens by dendritic cells is largely considered to be muted,
although robust Th2 responses may still be raised during infection.
Moreover, several studies have suggested the presence of non-
immunogenic helminth derived products. For example, the speciﬁc
Heligmosomoides polygyrus products that are recognised by the host
antibody response have recently been reported to be limited and
transfer of immune sera against these recognised proteins was
not sufﬁcient to alter the persistence of infection, suggesting that
the immunomodulators thatmaintain chronic infectionmay be dis-
tinct from the dominant immunogenic proteins recognised by the
host immune system (Hewitson et al., 2011a). Furthermore, anti-
body responses raised against H. polygyrus proteins were found to
be predominantly directed against glycan motifs. Therefore, a fur-
ther possibility is that potent helminth derived immunomodulators
that are recognised by the host immune response can be modiﬁed
in order to remove the immunogenic epitopes and thus, enhance
their longevity as therapeutics. It is not known to date whether
many of the current candidate helminth immunomodulators are
neutralised following repeat treatments in the host and it is clear
that focused studies are required in order to determine whether
currently researched candidates maintain their efﬁcacy after long
term application in chronic and recurring inﬂammatory diseases.4. Why it is too early to discount mouse models
Current research into helminth immunomodulation tends to be
focused mostly on murine systems and in his opinion articleProf. Pritchard calls for a reduction in the use of mouse disease
models in order to investigate the mechanisms of helminth immu-
nomodulation. Although mouse models have taught immunolo-
gists a lot about the pathogenesis of human disease it is clear
that many murine disease models represent an optimised system
that may apply to only a narrow range of human patients. Indeed
it is important to begin to transfer our knowledge of helminth
immunomodulation from experimental mouse models into human
systems and to test candidate products on human material when-
ever possible. However, the latter comes with considerable limita-
tions. Firstly, application of live parasite products into human
patients requires a signiﬁcant investment of time and money in or-
der to carry out safe and ethical clinical trials. Secondly, immuno-
logical analyses with human samples are largely limited to assays
based around peripheral blood mononuclear cells (PBMCs) derived
from donor blood, as tissue biopsies are often very difﬁcult to ob-
tain in sufﬁcient numbers. Investigation of helminth derived prod-
ucts in PBMC based assays will go a long way to determining
whether such therapies may be efﬁcacious in human subjects,
but such systems are also not a good indicator of local tissue re-
sponses and key inﬂammatory cell types such as macrophages,
which are not present outside of the tissues. In contrast, murine
systems give researchers access to unparalleled tools and yield
information that is simply unobtainable in their absence. For
example, work with transgenic mice or cytokine reporter mice
can provide invaluable information regarding the mechanisms by
which the immune system of the host is stimulated and modulated
by helminths and their products. In this respect, it is important to
note that since the ﬁrst trials reporting efﬁcacy of T. suis ova ther-
apy in colitis and Crohn’s disease patients, little new information
has become available regarding the basic biology or immunological
mechanisms through which this therapy functions despite Phase II
clinical trials being already underway. Critically, a better under-
standing of the cellular networks and mechanisms through which
immunomodulation by helminth products works will allow for the
reﬁnement and progression of treatments – in particular, the abil-
ity to generate pharmacological mimics or drugs that stimulate the
same identiﬁed pathways to induce suppression. This approach
would also ultimately reduce the need for exposure to any parasite
material and thus, negate any fears about immunogenicity and side
effects. Thus, mouse models are still needed to provide important
information about the underlying mechanisms of therapeutic hel-
minth infection and provide a research and development tool with
which to screen for potential problems. Nonetheless, it is clear that
work in mouse models can only go so far as to predict possible
mechanisms of action and may not highlight side effects that could
occur in other species. Studies in large animal models with a more
similar biology to humans, such as pigs and non-human primates,
will therefore be necessary in transitioning any ﬁndings from the
lab and in developing candidate helminth derived therapies.5. Moving forward
To further develop live-helminth therapy, or helminth-derived
product based therapies, an increased dialogue between academic
researchers and the pharmaceutical industry is needed in order to
maximise the chances of developing successful treatments. The
development of deﬁned helminth-derived products seems to be
advantageous in the long term as it allows for the production of
high quantities of safe, consistent product that can be produced
without the need for intermediate animal hosts and which may
ultimately be used in combination should such an approach prove
more efﬁcacious than administration of single helminth-derived
products. The pharmaceutical industry will play an essential role
in testing any candidate proteins for safety and efﬁcacy in humans
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the clinical trials and investments necessary for making such ther-
apy a reality. As such, basic laboratory studies will need to focus on
proving efﬁcacy and modes of action where possible, while also
cooperating with potential investors and developers to ensure
the candidate is a ﬁnancially viable and unique product in addition
to being an efﬁcacious biological. Increased interactions and joint
initiatives between academic researchers, clinicians and pharma-
ceutical companies may help to accelerate these processes and
establish priorities and should be established as soon as possible
to build on the potential of current candidates.
6. Summary
Recent advances in the ﬁeld of parasite immunology have led to
a better understanding of the mechanisms by which helminth
infections modulate the immune system of their hosts in order to
facilitate their long term survival. The resulting immunomodula-
tion of bystander immune responses has strong potential for
exploitation in a therapeutic setting. Recent increases in transcrip-
tomic and proteomic information will likely identify further prom-
ising candidates and thus, in order to proceed researchers must
consider which factors and criteria are most important in order
to yield successful treatments that can be adapted for the clinics.
A better understanding of the speciﬁc target cells and cellular path-
ways addressed by helminth derived immunomodulators and the
longevity of therapeutic effects will likely lead to new therapeutic
approaches.
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